R&D Increasing trial efficiency: Adityo Prakash talks small data... Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
News Click claims FDA okay for first-in-class schizophrenia DTx Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
